Compare Enact Holdings Inc (ACT) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enact Holdings Inc vs GeneDx Holdings Corp — how do they compare? Enact Holdings Inc trades at $46.28 (market cap $6.36B), while GeneDx Holdings Corp trades at $63.61 (market cap $1.90B). The key difference: Enact Holdings Inc is far larger — about 3.3× GeneDx Holdings Corp's market cap, and Enact Holdings Inc pays a 2.07% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enact Holdings Inc for 27 Days and GeneDx Holdings Corp for 20 Days on average.
| ACT | WGS | |
|---|---|---|
Market Cap | $6.36B | $1.90B |
Volume | 395,929 | 644,169 |
Sector | Financials | Health |
52-Week High | $50.07 | $167.51 |
52-Week Low | $34.93 | $34.51 |
Typical Hold Time | 27 Days | 20 Days |
Enterprise Value | $6.66B | $1.93B |
Dividend Yield | 2.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACT trades at $46.28, up 1.34% with neutral technical signals. The company shows strong profitability with 54.51% net income margin and trades at attractive valuations (P/E 9.76). Recent earnings beat expectations in Q2 2026, and the company maintains a robust capital position with positive ratings upgrades from AM Best in September 2026.
The outlook remains balanced with analyst consensus at Hold (55.56%) and a $45 price target. Strong fundamentals and shareholder returns via buybacks and dividends support upside, though negative cash flow trends and competitive pressures present risks. The stock offers value but requires monitoring of cash flow sustainability.
GeneDx (WGS) trades at $63.61, down 9.41% on the day amid a bearish technical signal. The company reported mixed quarterly earnings with a recent Q2 2026 beat but a net loss margin of -23.4% for 2026. Revenue growth is present, reaching $454M in 2026, yet profitability remains a challenge with negative ROE and ROA. Positive developments include new product launches and strong analyst buy ratings.
The outlook hinges on execution toward profitability; high valuation multiples like EV/EBITDA of 161.17 pose risk, but the consensus price target of $81 suggests upside if operational improvements materialize. Key risks include sustained losses and competitive pressures in genomics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enact Holdings Inc
Enact Holdings is a leading private mortgage insurance provider in the U.S. It partners with lenders to offer credit enhancement and risk management solutions, helping more borrowers achieve and maintain homeownership.
Read more on ACT →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
